SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2022
Commission File Number: 001-34563
CONCORD MEDICAL SERVICES HOLDINGS LIMITED
Room 2701-05, Tower A, Global Trade Center
36 North Third Ring Road East, Dongcheng District
People’s Republic of China
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|CONCORD MEDICAL SERVICES HOLDINGS LIMITED|
|By:||/s/ Jianyu Yang|
|Title:||Chairman and Chief Executive Officer|
Date: June 1, 2022
Concord Medical Announces Its Subsidiary’s Application Filing for Potential Listing on The Stock Exchange of Hong Kong Limited
BEIJING, June 1, 2022 /PRNewswire/ -- Concord Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced that its subsidiary, Concord Healthcare Group Co., Ltd. (“Concord Healthcare”), a company incorporated in China, filed an application (the “Application”) to list a minority stake of its shares (the “Concord Healthcare Shares”) on The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) (the “Listing”) on May 31, 2022. The Application is accessible through the Hong Kong Stock Exchange’s website at www.hkexnews.hk.
Shareholders are cautioned not to give undue reliance on this announcement. There can be no assurance whether and when the Listing will be completed. The Listing is subject to the approval from the Listing Committee of the HKSE for listing of, and permission to deal in, the Concord Healthcare Shares, and the final decisions of the respective board of directors of the Company and Concord Healthcare with respect to a number of factors, including but not limited to, valuation and prevailing market conditions.
This announcement is not intended to, and does not, constitute an offer to sell or a solicitation of an offer to purchase any securities, in the United States or elsewhere, and it is not intended to, and does not, constitute an offer, solicitation or sale of any securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.
About Concord Healthcare
Concord Healthcare is a leading oncology healthcare total solution platform in China featuring the research and application of advanced oncology diagnostic and treatment technologies, and one of the few private medical institutions in China owning multiple proton therapy treatment rooms. Concord Healthcare serves both cancer patients through self-owned medical institutions and empowerment to third-party medical institutions through network business. In its self-owned medical institutions, Concord Healthcare provides a full spectrum of oncology healthcare services to cancer patients across the entire care continuum, leveraging its high-caliber multidisciplinary team specialists and robust diagnosis and treatment capabilities featuring precision radiation therapy. Through its network business, Concord Healthcare empowers a widespread network of enterprise customers, primarily hospitals, with integrated oncology-related services, including primarily medical solution, management and technical support, and operating lease.
About Concord Medical
Concord Medical Services Holdings Limited (NYSE: CCM) is a healthcare provider featuring a full cycle of premium oncology services including cancer diagnosis, treatment, education and prevention. The Company focuses on providing multidisciplinary cancer care in all aspects of oncology healthcare services in its cancer hospitals and equipping them with technologically advanced equipment such as the state-of-the-art proton therapy system. The Company is striving to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics as well as partnered hospitals across China. For more information, please see http://ir.ccm.cn.
Safe Harbor Statement
This announcement contains forward-looking statements. These forward-looking statements can be identified by words or phrases such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar expressions. Forward-looking statements are inherently subject to uncertainties and contingencies beyond the Company’s control and based upon premises with respect to future business decisions, which are subject to change. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
For investor and media inquiries, please contact:
Concord Medical Services Holdings Limited
Manager of Investor Relations